Claudia Jurberg, writing in Intellectual Property Watch, reports that Brazil’s lower house of Congress held a hearing last month in which it discussed proposed changes to rules on pharmaceutical patents that would limit patents on (i) second-use drugs and (ii) polymorphs.
Both these areas are controversial. Critics say that second-use drugs are not truly novel or inventive because their medicinal function is already known, while polymorphs are just a way of retaining patent protection in respect of different versions of the same product. Supporters however point out that the costs of R&D and trialling of any drug are immense and the return is uncertain: absence of patent protection will steer R&D away from getting more and better uses from existing products which have known therapeutic effects, which may not be advantageous for patients.
Should the EU unify copyright laws?
19 hours ago